Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Colorectal Neoplasms 5Biliary Tract Neoplasms 4Colonic Neoplasms 3Sarcoma 2Rectal Neoplasms 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Uterine Cervical Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Solid Tumor 1Small Cell Lung Carcinoma 1Rare Tumour 1Piebaldism 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Multiple Primary 1Neoplasm Metastasis 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Dermatofibrosarcoma 1

Interventions

tremelimumab 1pembrolizumab 1envafolimab 1durvalumab 1Paclitaxel 1Endostatins 1Drug Therapy 1Carboplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Squamous Non-small Cell Lung Cancer × envafolimab × Clear all
NCT05243355 2022-02-17

Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC

Qilu Hospital of Shandong University

Phase 2 Unknown
46 enrolled
Thoracic

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡